Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype August 27, 2020 Publications VIEW PUBLICATIONS ⟶ Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia August 23, 2020 Publications VIEW PUBLICATIONS ⟶ Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment July 22, 2020 Publications VIEW PUBLICATIONS ⟶ Monitoring minimal residual disease in the bone marrow using next generation sequencing January 17, 2020 Publications VIEW PUBLICATIONS ⟶ Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a "Spike-in" Clonal Sequence November 13, 2019 Publications VIEW PUBLICATIONS ⟶ Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma October 1, 2019 Publications VIEW PUBLICATIONS ⟶ Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms March 21, 2019 Publications VIEW PUBLICATIONS ⟶ A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations August 25, 2018 Publications VIEW PUBLICATIONS ⟶ Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL August 22, 2018 Publications VIEW PUBLICATIONS ⟶ Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) August 9, 2017 Publications VIEW PUBLICATIONS ⟶
Publications2019-09-18T18:25:31+00:00
FEATURED PUBLICATIONS
LATEST PUBLICATIONS

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

October 1st, 2019|

VIEW PUBLICATION ⟶

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

August 22nd, 2018|

VIEW PUBLICATION ⟶

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

August 9th, 2017|

VIEW PUBLICATION ⟶

Load More Posts
POSTERS

2019

AMP

2018

AMP
EHA

2017

AMP
EHA

2016

AMP

2015

AMP
EHA
LATEST PUBLICATIONS

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

October 1st, 2019|

VIEW PUBLICATION ⟶

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

August 22nd, 2018|

VIEW PUBLICATION ⟶

Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)

August 9th, 2017|

VIEW PUBLICATION ⟶

Load More Posts
POSTERS

2019

AMP

2018

AMP
EHA

2017

AMP
EHA

2016

AMP

2015

AMP
EHA